Get the Stockscreener App
8.10
3.28%
-0.275
After Hours:
8.15
0.05
+0.62%
Personalis Inc stock is traded at $8.10, with a volume of 1.16M.
It is down -3.28% in the last 24 hours and down -12.53% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$8.375
Open:
$8.53
24h Volume:
1.16M
Relative Volume:
0.79
Market Cap:
$719.32M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-3.60
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
+3.18%
1M Performance:
-12.53%
6M Performance:
+13.13%
1Y Performance:
+44.64%
1-Day Range:
$8.02
$8.54
1-Week Range:
$7.73
$9.74
52-Week Range:
$2.8262
$11.40
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
8.10 | 743.74M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
618.86 | 227.87B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
238.37 | 165.99B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
713.35 | 56.89B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
148.52 | 41.32B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
IQV
Iqvia Holdings Inc
|
242.41 | 41.42B | 15.90B | 1.28B | 2.21B | 7.2842 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
Personalis (PSNL) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
BTIG Reiterates Buy Rating for Personalis (PSNL) with $12 Target - GuruFocus
Is Personalis Inc. stock attractive for long term wealth building2025 Historical Comparison & Expert Curated Trade Setups - ulpravda.ru
Why Personalis Inc. stock remains a top recommendationJuly 2025 Market Mood & Risk Controlled Stock Alerts - ulpravda.ru
Is Personalis Inc. stock attractive for hedge fundsEarnings Recap Summary & Consistent Return Strategy Ideas - ulpravda.ru
Personalis (PSNL) Achieves Remarkable Growth in Clinical Volumes - GuruFocus
Can Personalis Inc. stock outperform in 2025 bull marketGap Down & Real-Time Buy Zone Alerts - ulpravda.ru
Is Personalis Inc. stock a buy for dividend growth2025 Macro Impact & Real-Time Chart Breakout Alerts - ulpravda.ru
Will Personalis Inc. stock remain a Wall Street favoriteQuarterly Portfolio Report & Risk Adjusted Swing Trade Ideas - ulpravda.ru
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent Highlights - BioSpace
PSNL Achieves Key Medicare Coverage Milestone for Breast Cancer - GuruFocus
Personalis reports select preliminary fourth quarter and full year 2025 results - MarketScreener
Institutional Investors Are Personalis, Inc.'s (NASDAQ:PSNL) Biggest Bettors and Were Rewarded After Last Week's US$105m Market Cap Gain - 富途牛牛
Personalis (NASDAQ:PSNL) delivers shareholders splendid 54% CAGR over 3 years, surging 15% in the last week alone - simplywall.st
Personalis (NASDAQ:PSNL) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Will Personalis Inc stock remain a Wall Street favoriteJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - moha.gov.vn
Quant Funds Rotate Into Pavna Industries Limited StockTechnical Analysis Insights & Stay Invested. Stay Smart. - earlytimes.in
Morgan Stanley Analyst Initiates Equal Weight Rating On Personalis, Inc. (PSNL) - Insider Monkey
Personalis Outpaces The Market With Cancer Test Breakthroughs - Finimize
Would You Still Hold Personalis Stock If It Fell Another 30%? - Trefis
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Personalis, Inc. (NASDAQ:PSNL) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Will Personalis Inc. (04X) stock split increase liquidityRate Cut & Entry and Exit Point Strategies - Улправда
How Personalis Inc. stock reacts to bond yieldsWeekly Trading Summary & Safe Entry Point Alerts - ulpravda.ru
Personalis (NASDAQ:PSNL) Sees Strong Trading VolumeHere's Why - MarketBeat
Nasdaq Moves: How Personalis Inc. stock reacts to bond yieldsWeekly Stock Recap & Reliable Price Action Trade Plans - ulpravda.ru
Aug Opening: How risky is Personalis Inc. stock nowTrade Exit Summary & Daily Price Action Insights - Улправда
Revenue Check: Will Personalis Inc. (04X) stock split increase liquidityJuly 2025 Price Swings & Daily Price Action Insights - Улправда
How risky is Personalis Inc. stock nowJuly 2025 Earnings & Safe Investment Capital Preservation Plans - Улправда
Personalis study shows cancer blood test predicts immunotherapy outcomes By Investing.com - Investing.com Nigeria
Personalis study shows cancer blood test predicts immunotherapy outcomes - Investing.com
Personalis announces new publication applying ultrasensitive ctDNA testing - marketscreener.com
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors - Business Wire
About Us - FinancialContent
Personalis (NASDAQ:PSNL) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Personalis (NASDAQ:PSNL) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer - Business Wire
Why Analysts See Personalis Story Shifting With Medicare Tailwinds And Biopharma Headwinds - Yahoo Finance
Personalis, Inc. $PSNL Shares Purchased by Blue Water Life Science Advisors LP - MarketBeat
Personalis, Inc. (NASDAQ:PSNL) Stocks Shoot Up 38% But Its P/S Still Looks Reasonable - 富途牛牛
Personalis (NASDAQ:PSNL) Stock Price Down 4.8%What's Next? - MarketBeat
Personalis (NASDAQ:PSNL) Cut to Sell at Wall Street Zen - MarketBeat
Is Personalis Inc. (04X) stock undervalued by metricsEarnings Miss & Short-Term High Return Strategies - Newser
Geode Capital Management LLC Buys 851,422 Shares of Personalis, Inc. $PSNL - MarketBeat
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Personalis Inc Stock (PSNL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tachibana Aaron | CFO AND COO |
Nov 25 '25 |
Sale |
10.78 |
103,668 |
1,117,541 |
164,458 |
1.12%
0.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):